Publication:
Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma.

dc.contributor.authorNavarro, Natalia
dc.contributor.authorMolist, Carla
dc.contributor.authorSansa-Girona, Júlia
dc.contributor.authorZarzosa, Patricia
dc.contributor.authorGallo-Oller, Gabriel
dc.contributor.authorPons, Guillem
dc.contributor.authorMagdaleno, Ainara
dc.contributor.authorGuillén, Gabriela
dc.contributor.authorHladun, Raquel
dc.contributor.authorGarrido, Marta
dc.contributor.authorSegura, Miguel F
dc.contributor.authorHontecillas-Prieto, Lourdes
dc.contributor.authorde Álava, Enrique
dc.contributor.authorPonsati, Berta
dc.contributor.authorFernández-Carneado, Jimena
dc.contributor.authorAlmazán-Moga, Ana
dc.contributor.authorVallès-Miret, Mariona
dc.contributor.authorFarrera-Sinfreu, Josep
dc.contributor.authorde Toledo, Josep Sánchez
dc.contributor.authorMoreno, Lucas
dc.contributor.authorGallego, Soledad
dc.contributor.authorRoma, Josep
dc.date.accessioned2023-05-03T13:26:23Z
dc.date.available2023-05-03T13:26:23Z
dc.date.issued2022-10-11
dc.description.abstractThe majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox, since more than 90% of cancer deaths are attributable to metastatic progression. Integrin alpha9 (ITGA9) has been previously described as playing an essential role in metastasis; however, little is known about the mechanism that links this protein to this process, being one of the less studied integrins. We have now deciphered the importance of ITGA9 in metastasis and provide evidence demonstrating its essentiality for metastatic dissemination in rhabdomyosarcoma and neuroblastoma. However, the most translational advance of this study is to reveal, for the first time, the possibility of reducing metastasis by pharmacological inhibition of ITGA9 with a synthetic peptide simulating a key interaction domain of ADAM proteins, in experimental metastasis models, not only in childhood cancers but also in a breast cancer model.
dc.identifier.doi10.1007/s00018-022-04557-y
dc.identifier.essn1420-9071
dc.identifier.pmcPMC9553833
dc.identifier.pmid36221013
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553833/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s00018-022-04557-y.pdf
dc.identifier.urihttp://hdl.handle.net/10668/19542
dc.issue.number11
dc.journal.titleCellular and molecular life sciences : CMLS
dc.journal.titleabbreviationCell Mol Life Sci
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.page.number546
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCancer
dc.subjectDissemination
dc.subjectPaediatric cancer
dc.subjectProgression
dc.subjectSolid tumours
dc.subject.meshADAM Proteins
dc.subject.meshHumans
dc.subject.meshIntegrin alpha Chains
dc.subject.meshIntegrins
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeuroblastoma
dc.subject.meshRhabdomyosarcoma
dc.titleIntegrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number79
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9553833.pdf
Size:
2.56 MB
Format:
Adobe Portable Document Format